Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Application symbols : Abbv save search
U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma
Published: 2024-02-27 (Crawled : 01:00) - globenewswire.com
GNMSF | $290.38 3.83% 220
|
Health Technology
|
| O: -0.28%
H: 1.46%
C: 1.46%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.13%
H: 0.0%
C: 0.0%
GMAB | $28.72 1.38% 1.36% 360K
|
Health Technology
|
| O: -1.6%
H: 1.11%
C: 0.41%
epkinly fda license review application
AbbVie Provides Regulatory Update on ABBV-951 (Foscarbidopa/Foslevodopa) New Drug Application
Published: 2023-03-22 (Crawled : 13:00) - prnewswire.com
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -0.7%
H: 0.77%
C: -1.29%
abbv-951 drug abbvie update application
AbbVie Submits Supplemental New Drug Application to U.S. FDA to Support New Indication of LINZESS® (linaclotide) for Functional Constipation in Children and Adolescents 6 to 17 Years of Age
Published: 2022-12-16 (Crawled : 13:00) - prnewswire.com
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -0.64%
H: 0.78%
C: -0.97%
linzess fda drug children application
U.S. FDA Accepts for Priority Review the Biologics License Application for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma
Published: 2022-11-21 (Crawled : 14:00) - biospace.com/
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.27%
H: 2.08%
C: 1.1%
cd20 duobody treatment fda application license review
Genmab Announces That AbbVie Will Submit Marketing Authorization Application to European Medicines Agency for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Published: 2022-07-18 (Crawled : 14:20) - globenewswire.com
GNMSF | $290.38 3.83% 220
|
Health Technology
|
| O: 0.15%
H: 4.93%
C: 2.47%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 1.42%
H: 0.0%
C: 0.0%
GMAB | $28.72 1.38% 1.36% 360K
|
Health Technology
|
| O: 0.82%
H: 1.15%
C: -1.16%
cd20 duobody treatment application authorization
AbbVie Submits Marketing Authorization Application to EMA for Atogepant for the Preventive Treatment of Migraine
Published: 2022-07-18 (Crawled : 07:00) - prnewswire.com
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 1.42%
H: 0.0%
C: 0.0%
treatment ema application migraine authorization
AbbVie Submits Supplemental New Drug Application to U.S. FDA for Atogepant (QULIPTA™) to Support Label Expansion for the Preventive Treatment of Migraine
Published: 2022-06-21 (Crawled : 14:00) - biospace.com/
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 1.48%
H: 0.0%
C: 0.0%
treatment fda expansion drug label application migraine
Ascletis Announces Submission of Marketing Authorization Applications for Ritonavir in Eight Additional European Countries
Published: 2022-03-01 (Crawled : 10:00) - prnewswire.com
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.99%
H: 0.0%
C: 0.0%
europe application authorization submission
AbbVie Submits Supplemental New Drug Application to U.S. FDA for cariprazine (VRAYLAR®) for the Adjunctive Treatment of Major Depressive Disorder
Published: 2022-02-22 (Crawled : 14:30) - biospace.com/
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -1.93%
H: 3.61%
C: 3.05%
vraylar new drug treatment fda order application drug major depressive disorder
Global Anesthetic Drugs Market (2021 to 2026) - by Drug Type, Route of Administration, Application and Geography
Published: 2022-02-18 (Crawled : 16:00) - prnewswire.com
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: -0.64%
H: 0.0%
C: -2.99%
TEVA | $12.86 0.63% 0.0% 10M
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -2.04%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -0.19%
H: 0.72%
C: -0.46%
ABT | News | $107.28 1.91% 0.18% 10M
|
Health Technology
|
| O: -0.48%
H: 0.26%
C: -2.67%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -1.02%
H: 0.43%
C: -0.84%
application drug
Outlook on the Inhalation Anesthesia Global Market to 2026 - by Product, Application, End-user and Region
Published: 2021-12-02 (Crawled : 18:00) - prnewswire.com
CTS S | $43.43 0.77% 0.0% 120K
|
Electronic Technology
|
| O: 0.51%
H: 3.16%
C: 2.4%
BAX | $39.47 -0.45% 0.0% 2.8M
|
Health Technology
|
| O: -0.25%
H: 2.3%
C: 1.79%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.16%
H: 0.0%
C: 0.0%
application
AbbVie Submits Application for Risankizumab (SKYRIZI®) in Moderate to Severe Crohn's Disease to European Medicines Agency (EMA)
Published: 2021-11-30 (Crawled : 13:30) - biospace.com/
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -0.35%
H: 0.0%
C: 0.0%
ema europe application disease risankizumab
Global $191 Billion Orphan Drugs Markets to 2026: Therapeutic Applications in Rare and Orphan Diseases, Regulatory Framework, Patents, and Innovations
Published: 2021-08-05 (Crawled : 20:00) - prnewswire.com
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -0.85%
H: 0.15%
C: -0.16%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.16%
H: 0.0%
C: 0.0%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.12%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.26%
H: 0.0%
C: 0.0%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -2.02%
H: 0.09%
C: -1.38%
disease drug patent application rare
AbbVie Submits Regulatory Applications for SKYRIZI® (risankizumab) in Psoriatic Arthritis to FDA and EMA
Published: 2021-04-07 (Crawled : 13:15) - prnewswire.com
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.14%
H: 0.57%
C: -0.3%
fda risankizumab ema application
Allergan, an AbbVie Company, Submits New Drug Application for Investigational AGN-190584 for the Treatment of Presbyopia
Published: 2021-02-25 (Crawled : 14:00) - biospace.com/
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -0.19%
H: 0.76%
C: -1.06%
treatment drug new drug application presbyopia
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.